Physician profile
Robert E Hall
NPI 1316941396
$4,329.86
in general payments reported to CMS, 2019-2025
42 companies · $325 in 2025
The $325 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $836 · 2020: $562 · 2021: $1,059 · 2022: $744 · 2023: $521 · 2024: $284 · 2025: $325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,129.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $575.74 | 2019-2025 | Prolia, Evenity, Otezla |
| Astellas Pharma US INC | $457.87 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $382.15 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $377.76 | 2019-2025 | |
| Lilly USA, LLC | $291.36 | 2019-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $275.14 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Amarin Pharma, INC. | $172.06 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $155.61 | 2020-2024 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $128.23 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.65 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $111.87 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $84.82 | 2022 | |
| Merck Sharp & Dohme LLC | $84.12 | 2019-2024 | Belsomra, Verquvo, Steglatro |
| Glaxosmithkline, LLC. | $82.79 | 2021-2025 | Arexvy, Shingrix |
| Medtronic, INC. | $78.40 | 2021-2025 | Minimed 780g |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.